About BresaGen

About company

BresaGen is a developer of proteins and peptides, especially biogenerics. In October 2006, BresaGen was sold to Hospira Inc of the US, and Paragon made a 2.35x return on investment, and 135% IRR. Hospira acquired the company to further develop BresaGen’s intellectual property, and to distribute its products in the US.